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Abstract:  Patients  with  chronic  lymphocytic  leukemia  (CLL)  have  benefited  from  the 
introduction  of  targeted  therapy  for  leukemia.  Rituximab  (a  chimeric  murine-derived 
monoclonal antibody that targets CD20 on lymphocytes) was the first monoclonal antibody 
to affect the natural course of this disease. Several reports have shown modest single-agent 
activity in patients with CLL. However, the best results come from the combination of this 
agent with chemotherapy; a significant benefit has been seen with the use of fludarabine, 
cyclophosphamide, and rituximab (FCR). The addition of rituximab to chemotherapy boosted 
overall response rates, complete response rates and prolonged progression free survival. Recent 
data showed an overall survival benefit with FCR. Other combinations including bendamustine 
and rituximab appear more effective than bendamustine alone, while combining rituximab with 
other types of agents also appears to improve response rates. This type of relatively nontoxic 
regimen is being investigated in elderly patients who may not tolerate standard combination 
chemoimmunotherapies.
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Introduction
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western 
world. It is estimated that 15,490 patients will be diagnosed and 4,390 will die of CLL 
in 2009 in the USA.1 It is considered by the World Health Organization (WHO) to be 
one of the indolent mature B-cell neoplasms and is classified with small lymphocytic 
lymphomas.2 CLL is diagnosed by the presence of a typical B-cell immunophenotype 
and co-existence of CD5+/CD19+/CD20+/HLA-DR+/CD23+/sIg dim.3,4 Monoclonal 
antibodies targeting CD20 have been evaluated in the treatment of CLL due to wide 
expression of this surface antigen on leukemic cells. CD20 is a calcium channel that 
interacts with the B-cell immunoglobulin receptor complex (BCR) and is present on 
both normal and malignant B-cells.5 It is important to note that the antigen density of 
CD20 on CLL cells is significantly less than that seen in lymphoma.
Rituximab
Rituximab is a chimeric murine-derived monoclonal antibody that consists of a human 
IgG1-k constant regions and variable regions from the murine monoclonal anti-CD20 
antibody IDEC-2B8. It recognizes CD20 and activates complement and promotes C3b 
deposition in close proximity to cell-bound rituximab. Rituximab exerts its actions via 
several pathways including antibody-dependent cellular activity (ADCC), complement-
dependent cytotoxicity (CDC), and through apoptosis via activation of caspase 3.6,7 Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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Resistance to rituximab in cell lines has been linked to the 
presence of surface antigens such as CD55 and CD59; which 
block CDC/ADCC.8,9
Maloney et al evaluated rituximab in a phase I study 
using a single dose of 10–50 mg/m2 in patients with relapsed 
B-cell non-Hodgkin lymphoma (NHL) and then obtained 
biopsies two weeks later to confirm binding of the antibody. 
They showed rapid depletion of B-cells, positive binding to 
tumor cells, and no dose limiting toxicity.10 Another phase 
I study used rituximab weekly × 4 at doses of 125, 275, and 
375 mg/m2 in patients with relapsed lymphoma.11 Six of 
14 patients (40%) with low grade lymphoma responded and 
375 mg/m2 was selected for phase II studies.
Single-agent rituximab
McLaughlin et al authored the pivotal phase II study in 1998 
using rituximab 375 mg/m2 IV weekly × 4 in patients with 
relapsed low grade lymphoma; 48% responded, the response 
rate was only 13% in patients with small lymphocytic 
lymphoma (SLL).12 Several other studies reported similar 
response rates (Table 1).13–17 In an attempt to improve the 
efficacy of rituximab, 2 trials evaluated higher doses or more 
frequent administration. Doses of 500 mg/m2 to 2250 mg/m2 
IV weekly × 4 were given to 40 patients with CLL yielding an 
overall response rate (ORR) of 29% at a dose of 500 mg/m2 
and 75% at a dose of 2250 mg/m2. All responses were partial 
remission (PR) and time to progression (TTP) was 8 months.18 
Thrice weekly rituximab at 375 mg/m2 × 4 weeks was evaluated 
by Ohio State University in 33 patients with SLL/CLL; this 
produced an ORR of 45%; one complete remission (CR) was 
seen.19 Rituximab has also been evaluated as frontline therapy 
for CLL. Hainsworth et al assessed rituximab 375 mg/m2 
IV weekly × 4 in untreated patients with CLL with maintenance 
rituximab for patients who had objective response or stable 
disease. This yielded a 9% CR and a 58% ORR;   progression 
free   survival (PFS) was 18.6 months.20 Thomas et al gave 
rituximab 375 mg/m2 IV weekly × 8 weeks to patients with 
previously untreated CLL with high beta-2 microglobulin but 
no standard indication for treatment; this provided an ORR of 
90% and a CR rate of 19%.21
Rituximab and chemotherapy
The Cancer and Leukemia Group B (CALGB) 9712 random-
ized 104 chemonaive patients to concurrent vs sequential 
fludarabine and rituximab (FR) therapy. Fludarabine was given 
at 25 mg/m2 IV days 1–5 every 28 days for 6 cycles while 
rituximab was given at 375 mg/m2 IV on day 1 of each cycle 
(an additional dose on cycle one day 4 was given to ensure 
adequate saturation of CD20 binding sites).22 Sequential 
rituximab 375 mg/m2 weekly × 4 was given 2 months after the 
end of fludarabine or FR if patients had at least stable disease 
or better per National Cancer Institute (NCI) criteria. Ninety 
percent ORR including 47% CR was achieved in the concur-
rent arm compared to 77% ORR and 28% CR in the sequential 
arm. However, in a recent update with a long-term follow 
up, there was no difference in PFS or overall survival (OS) 
between concurrent vs sequential arms; with an estimated 17% 
of responders still in remission 8 years later.23 The Europeans 
showed similar results in a multi-center phase II study using 
FR.24 A retrospective comparison between CALGB 9712 and 
9011 (single-agent fludarabine [F]) showed a superior ORR 
with FR vs F (84% vs 63%), as well as a superior 2-year PFS 
(67% vs 45%) and 2-year OS (93% vs 81%).25
MD Anderson Cancer Center (MDACC) evaluated flu-
darabine, cyclophosphamide and rituximab in both treated 
and untreated patients (Table 2). Fludarabine 25 mg/m2, 
cyclophosphamide 250 mg/m2 on days 2–4 of cycle one and on 
days 1–3 of cycles 2 – 6, and rituximab 375 mg/m2 on day 1 of 
cycle one and 500 mg/m2 on day 1 of cycles 2 – 6 (fludarabine, 
cyclophosphamide, and rituximab [FCR]) were given every 
28 days for a total of 6 cycles to 177 patients with relapsed 
CLL.26 The ORR was 73% with 25% CR, 16% nodular PR 
and 32% PR. Thirty-two percent of complete responders 
achieved molecular remission in the bone marrow. FCR was 
given to 300 patients with previously untreated CLL produc-
ing a 94% ORR, including a 72% CR rate, nodular partial 
remission in 10%, and partial remission due to cytopenia and 
residual disease in 7% and 6% respectively.27,28 Median time 
to progression was 80 months with a 6-year OS of 77%, and 
responses predicted longer survival.
Lamanna et al used another purine analogue, pentosta-
tin, in patients with relapsed CLL. Pentostatin 4 mg/m2, 
Table 1 Rituximab single agent trials
Ref Prior Rx N Doses (W) ORR% PFS/TTP
McLaughlin12 Y 30 4 13 ND
Nguyen13 Y 12 4 0 ND
Winkler14 Y 9 4 11 ND
Ladetto15 Y 7 4 0 ND
Huhn16 Y 28 4 25 TTP 16 w 
Itala17 Y 24 4 35 TTP 12.5 w
O’Brien18 Y 40 4 (500–2250) 36 TTP 8 m
Byrd19 Y 33 4 (thrice/w) 45 PFS 9 m
Hainsworth20 N 44 4 51 18.6 m
Thomas21,* N 21 8 21 ND
Note: *No standard indication for therapy, high risk features
Abbreviations: Ref, reference; Prior Rx, prior therapy; N, number of patients; 
ORR, overall response rate; PFS, progression free survival; TTP, time to progression; 
ND, not given; W, weekly.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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  cyclophosphamide 600 mg/m2 (starting cycle one) and 
  rituximab 375 mg/m2 (starting cycle two) (PCR) were given 
IV on day 1 every 3 weeks × 6 to 46 patients with relapsed 
CLL yielding an ORR of 75% including 25% CR.29 This 
regimen was assessed in the front-line setting by Kay et al 
in 64 previously untreated patients with CLL who received 
the combination of pentostatin 2 mg/m2, cyclophosphamide 
600 mg/m2 and rituximab 375 mg/m2 IV on day 1 every 3 
weeks × 6 cycles.30 Responses occurred in 91% including 
41% CR, 22% nodular PR, and 28% PR. This regimen was 
equally effective in young versus older patients and in those 
with del 11q22; 0/3 patients with 17p del reached CR.
Two phase III studies evaluated the comparison of fludara-
bine and cyclophosphamide (FC) to FCR in a   randomized 
trial.31,32 The German CLL Study Group (GCLLSG8) com-
pared FCR to FC in 817 previously untreated patients.31 
Patients were randomized to receive FC (fludarabine 
25 mg/m2 IV , and cyclophosphamide 250 mg/m2 IV days 1–3) 
or FCR (rituximab 375 mg/m2 IV day 0 in cycle 1 and 
500 mg/m2 day 1 of subsequent cycles) every 28 days × 6. 
ORR was 95% vs 88%, CR rate 52% vs 27% for FCR vs FC 
respectively. There was improved PFS (P , 0.0001 vs 0.18). 
Recently Hallek et al updated their results and showed an OS 
benefit at 37 months for FCR (84%) vs FC (79%) (P = 0.01); 
only patients in Binet stages A and B had a superior OS after 
FCR therapy.33 In the REACH study, 552 relapsed patients 
were randomized to FC vs FCR every 28 days for 6 cycles 
resulting in a 10-month gain in PFS with FCR.32
MDACC added alemtuzumab to the FCR combination in 
patients with heavily pretreated CLL.34 Alemtuzumab 30 mg 
IV was given on days 1, 3, 5, rituximab 375–500 mg/m2 
IV day 2, fludarabine 25 mg/m2 IV days 3–5, and cyclophos-
phamide 250 mg/m2 days 3–5 every 28 days for 6 cycles. Of 
the 74 patients who completed treatment, 24% achieved CR, 
2.7% nodular PR, and 37.8% PR (ORR 65%). In patients with 
17p del, 44% responded to cyclophosphamide, fludarabine, 
alemtuzumab, and rituximab (CFAR), while 19% of patients 
treated previously with FCR achieved CR on this regimen. 
Median survival for all patients was 19 months but more than 
35 months for patients achieving CR. This regimen was given 
by the same group to patients with previously untreated CLL 
with high risk features (beta-2 microglobulin .4) in a phase 
II study.35 The initial report on the first 21 patients showed 
71% CR, 5% nodular PR, PR in 19%. This has been recently 
updated with no significant change in response rates.36 There-
fore, it seems that CFAR does not provide better results than 
FCR as front-line therapy in these high risk patients.
Rituximab was also investigated in combination with 
bendamustine, a novel alkylating agent which contains a 
benzimidazole ring and is only partially cross-resistant with 
other alkylating agents in vitro. Eighty-one patients with 
relapsed CLL were treated in a phase II multi-center study 
using bendamustine 70 mg/m2 IV on days 1–2 combined with 
rituximab 375 mg/m2 for cycle one and 500 mg/m2 for cycles 
2–6 every 28 days. The ORR was 77% including 14.5% CR 
and 62.9% PR.37 Among the genetics subgroups, ORR was 
92.3% in 11q-, 100% in 12+ and 44.4% in patients with 17p 
del. Bendamustine combined with rituximab (BR) proved to 
be effective in 117 previously untreated patients with CLL 
yielding an ORR of 90.9% (including 32.7% CR).38
In summary, FCR appear to be the most effective front-
line regimen in CLL based on both single institutional and 
phase III randomized trial data. The MDACC data   indicated 
a CR rate of 72% and an ORR of 95%. The   German ran-
domized trial (of FCR vs FC) also produced a 95% ORR in 
the FCR arm. The CR rate dropped to 44%–50% (  including 
Table 2 Nucleoside analogues/rituximab trials
Ref Regimen Rituxan Prior Rx Phase N ORR% (CR%) PFS/TTP
Keating28 FCR 500 q 4w No II 300 95 (72) TTP 80 m 
Kay30 PCR 375 q 3w No II 64 91 (41) PFS 32.6 m
Hallek31 FCR 
FC
500 q 3w No III 817 95 (52) 
88 (27)
PFS 43 m 
PFS 32 m
Byrd22 FR con 
FR seq
375 q 4w No II 104 90 (47) 
77 (28)
NR 
NR
Schulz24 FR 375 q 4w 
(cycle 3)
No 
Yes
II 20 
11
85 (25) 
91 (45)
ND
Wierda26 FCR 500 q 3w Yes II 177 73 (25) PFS 28 m
Lamanna29 PCR 375 q 3w Yes II 46 75 (25) TTP 25 m 
Robak32 FCR 
FC
500 q 3w Yes III 552 70 (24) 
50 (13)
PFS 30.6 m 
PFS 20.6 m
Abbreviations: Ref, reference; Prior Rx, prior therapy; N, number of patients; ORR, overall response rate; CR, complete remission; PFS, progression free survival;   
TTP, time to progression; ND, not given; W, weekly; M, month; Con, concurrent; Seq, sequential; NR, not reached.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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uncertain CR), not surprising when single institutional data 
are reproduced in a large multicenter randomized trial. How-
ever, this is still the highest CR rate reported in patients with 
CLL. However some investigators have questioned whether, 
given the marked synergy seen when rituximab is added to 
chemotherapy, the alkylating agent is necessary. In other 
words would FR be as effective as FCR? The PFS with FR 
appears to be inferior to that reported with FCR. However, 
this question will be more definitively answered in the cur-
rent Intergroup trial comparing FCR to FR with or without 
lenalidomide maintenance (NCT00602459). While the CR 
rates with BR, in a smaller study, were inferior to those 
seen with FCR, the Germans are conducting a randomized 
study in frontline CLL of BR vs FCR (GCLLSG10, NCT 
00769522). PCR also appeared inferior to FCR; of interest 
is that FCR is clearly less well tolerated in patients over the 
age of 70 whereas PCR was as safe and effective in elderly 
patients.
Rituximab and non-chemotherapy agents
Alemtuzumab is a humanized monoclonal antibody that 
targets the CD52 antigen. CD52 is a 21–28 kD cell surface 
glycopeptide expressed on virtually all human lymphocytes, 
monocytes, macrophages, a small subset of granulocytes, but 
not erythrocytes, platelets or bone marrow stem cells. It has 
been FDA approved in both previously untreated and fludara-
bine refractory patients with CLL.39,40 Rituximab has been 
combined with alemtuzumab in several studies. Faderl et al 
gave rituximab 375 mg/m2 weekly × 4 with alemtuzumab 
using a loading-dose schedule of 3 mg, 10 mg, and 30 mg 
on 3 consecutive days during week 1 and 30 mg on day 3, 
5 of weeks 2–4 with a repeat course depending on response 
and toxicity.41 Twenty of 32 (63%) patients with relapsed 
CLL achieved response, including 6% CR. Median TTP was 
6 months and median OS was 11 months; 15% developed 
symptomatic CMV antigenemia requiring therapy. Mayo 
Clinic assessed this combination in 30 previously untreated 
patients with high risk features (del 17p13, del 11q22) and 
lacking a standard indication for therapy (early therapy) 
giving alemtuzumab 30 mg weekly × 4 and rituximab 
375 mg weekly × 4; this yielded an ORR of 90% including 
37% CR.42
Lenalidomide is an immunomodulatory drug that is a 
more potent analog of thalidomide and has shown activity 
in relapsed patients with CLL, including activity in patients 
with high-risk cytogenetics.43–45 Ferrajoli et al recently 
added rituximab 375 mg/m2 weekly × 4 then every 4 weeks 
on cycles 3–12 of lenalidomide 10 mg starting day 9 on 
cycle one and then daily every 28 days for 12 cycles.46 
After 6 cycles of therapy 25 of 37 patients achieved response 
(68%) including 6 patients with nodular PR, 19 PR, 6 SD; 
6 patients failed to respond. Patients with poor cytogenetics 
features did equally well. This compares favorably to single 
agent lenalidomide with superior ORRs and less tumor flare 
reaction.44
Rituximab has also been combined with high dose 
methylprednisolone. Glucocorticoids kill lymphoid cells 
by a p53 independent mechanism and appear to be active 
in patients with 17p deletions.47 They also reduce bulky 
lymphadenopathy and cause less myelosuppression than 
chemotherapy. Bowen et al reported data from a retrospective 
study wherein 37 previously treated patients with CLL were 
given 1 g/m2 of methylprednisolone daily × 5 and rituximab 
375 mg/m2 weekly × 4 with repeat of each cycle up to three.48 
Seventy-eight percent had an objective response, includ-
ing 5 of 9 patients with del 17p; however, 29% developed 
infectious complications before completing one month of 
therapy. Several other studies are summarized in Table 3. 
James et al tested this combination in 28 previously untreated 
patients using methylprednisolone 1 g/m2 daily × 3 every 28 
days with weekly rituximab (375 mg/m2 × 12 or 750 mg/m2 
weekly × 7).49 The ORR was 96% including 32% CR with 
better response if patients had less prominent splenomegaly 
and lower beta-2 microglobulin. This combination is proven 
to be effective but at the cost of a significant infection 
rate.
Finally, rituximab was evaluated in combination with 
human granulocyte macrophage colony stimulating fac-
tor (GM CSF); the rationale was the increased surface 
expression of CD20 seen on some CLL cells with the use 
of GM CSF in vitro.50 Ferrajoli et al gave GM CSF 250 µg 
SC thrice weekly × 8 and rituximab 375 mg/m2 weekly × 4 
to 118 patients with CLL (3 different groups; elderly previ-
ously untreated, high risk with elevated beta-2 microglobulin 
and no standard indication for therapy, relapsed patients) 
achieving 65% ORR including 9% CR with minimal side 
effects including mild GM CSF injection site erythema. 
These results compare favorably to historical control data 
using rituximab alone.51
Special conditions
Complications
It is known that some patients will experience fever, chills, 
nausea, vomiting, hypotension and dyspnea predominantly 
with their first infusion of rituximab. This is known as 
‘cytokine release syndrome’ and is associated with more Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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intense cellular expressions of CD20. Standard premedica-
tion with acetaminophen and diphenhydramine is warranted; 
many people also use steroids, at least before the first dose 
of rituximab. Thus, the initial infusion of rituximab is usu-
ally started slowly with a gradual escalation of the rate. 
Tumor lysis syndrome has been described with rituximab. 
Most investigators use allopurinol as well as hydration in 
patients with high volume disease. Progressive multifocal 
leukoencephalopathy (PML) is a demyelinating disorder of 
the brain caused by the reactivation of latent JC polyoma 
virus. Rituximab has been linked to PML in several diseases 
(especially SLE) and has been found to be associated with 
malignancy in 52/57 reported cases; 24.6% were CLL.52 
Those patients usually also received chemotherapy agents 
and seven patients had had prior hematopoietic stem cell 
transplant. The median time to diagnosis was 5.5 months 
from the last dose of rituximab and the median number 
of rituximab doses was 6. The case-fatality rate was 90%. 
Another viral reactivation concern is with patients who have 
had HBV infection. Several reports have documented HBV 
reactivation with the use of rituximab in patients with NHL 
and CLL, even with negative HBs Ag.53,54
elderly
Most published trials of CLL have reported a median age 
of less than 70, which does not reflect the general popula-
tion. Data with FCR suggest that patients .70 years old are 
less likely to complete six cycles, less likely to achieve CR, 
and tend to have more complications.28 Kay et al reported 
a   subanalysis of previously untreated patients older than 70 
years receiving PCR.55 Elderly patients had more delayed 
cycles (28% vs 7%), but there was no significant difference 
in the total number of cycles given, need for dose reductions, 
grade 3–4 hematologic, infectious, or other toxicities. In 
addition there was no significant difference in ORR, CR or 
even PFS between both younger and older patients.
Maintenance
Rituximab maintenance has been shown to prolong PFS 
in patients with NHL. Del Poeta et al gave FR (F 25 mg/m2 
daily × 5, every 28 days × 6, and then R 375 mg/m2 weekly × 4) 
to 75 previously untreated CLL patients; responders with pos-
itive minimal residual disease were given four monthly cycles 
of rituximab 375 mg/m2 followed by 12 monthly low dose 
(150 mg/m2) rituximab maintenance.56 Twenty-eight patients 
who received maintenance therapy had longer response 
duration (85% vs 32% at 5 years; P = 0.001) compared to 
18 patients who did not. However; no explanation was given 
for why the observation group did not receive maintenance, 
which makes the comparison specious. Foon et al introduced 
the FCR-Lite regimen with dose reduction of fludarabine and 
  cyclophosphamide, rituximab twice each cycle, and ritux-
imab 500 mg/m2 as maintenance every 3 months until relapse. 
Rituxan 375 mg/m2 was given on day 1 of cycle 1 then 500 mg 
on day 1 of cycle 2–6 and day 14 of cycle 1–6. Fludarabine 
20 mg/m2 and cyclophosphamide 150 mg/m2 were given 
for 3 days with each cycle. Fifty previously untreated CLL 
patients achieved 100% ORR (including 79% CR) with a 
Table 3 Rituximab trials using non-chemotherapy agents
Ref Regimen Dose Prior Rx N ORR% (CR%) PFS/TTP
Faderl41 Rituximab 
Alemtuzumab
qw × 4 
30 2/w × 4
Yes 32 63 (6) TTP 6 m 
Nabhan58 Rituximab 
Alemtuzumab
qw × 4 
3, 10, 30 3/w × 4
Yes 11 9 (0) ND
Zent42 Rituximab 
Alemtuzumab
qw × 4 
30 3/w × 4
No 30 90 (37) TTP 12.5 m
Frankfurt59 Rituximab 
Alemtuzumab
qw × 8 
30 3/w × 17
No 20 90 (75) NR
Ferrajoli46 Rituximab 
Lenalidomide
qw × 4 then qm × 10 
10 mg qd × 12m
Yes 37 68 (0) ND
Bowen48 Rituximab 
Methylprednisolone
qw × 4 
1 gm qd × 5
Yes 37 78 (22) PFS 12 m
Dungearwalla60 Rituximab 
Methylprednisolone
qw × 6 
1 gm qd × 5
Yes 14 93 (14) PFS 7 m
Castro61 Rituximab 
Methylprednisolone
qw × 4 
1 gm qd × 5
Yes 14 93 (36) TTP 15 m
James49 Rituximab 
Methylprednisolone
375 qw ×12 or 750 qw × 9 
1 gm qd × 3
No 28 96 (32) NR
Abbreviations: Ref, reference; Prior Rx, prior therapy; N, number of patients; ORR, overall response rate; CR, complete remission; PFS, progression free survival;   
TTP, time to progression; ND, not given; NR, not reached; qw, weekly; qm, monthly; qd, daily.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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median duration of complete response of 22.3 + months 
and no relapse yet seen in   complete   responders.57 Grade 3–4 
neutropenia was noted in 13% of the cycles which compares 
favorably to historical data using standard FCR. Further 
evaluation of this regimen is warranted. There are, as yet, 
no data from randomized trials of maintenance rituximab in 
CLL to establish the benefit of this approach.
Conclusion
In conclusion, rituximab has improved the management of 
CLL and has become a critical agent in most combination 
regimens. It increases CR and ORRs, and prolongs PFS. 
FCR appears to be the best front-line regimen with a survival 
benefit seen over chemotherapy alone. Non-chemotherapy-
based combinations with rituximab may offer safe and 
effective options for patients who cannot tolerate chemoim-
munotherapy. Consolidation and maintenance therapies 
remain interesting areas of research but randomized trials 
are needed.
Disclosures
The authors report no conflicts of interest in this work.
References
1.  SEER Cancer Statistics Review, 1975–2006, National Cancer Institute. 
Bethesda, MD. 2009. http://seer.cancer.gov/csr/1975_2006/.
2.  Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid 
neoplasms: the microscope as a tool for disease discovery. Blood. 
2008;112(12):4384–4399.
3.  Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-
sponsored Working Group guidelines for chronic lymphocytic 
  leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 
87(12):4990–4997.
4.  Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis 
and treatment of chronic lymphocytic leukemia: a report from the 
International Workshop on Chronic Lymphocytic Leukemia updating 
the National Cancer Institute-Working Group 1996 guidelines. Blood. 
2008;111(12):5446–5456.
5.  Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo 
by a chimeric mouse human monoclonal antibody to CD20. Blood. 
1994;83(2):435–445.
6.  Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell   clearance 
by rituximab in vivo in patients with B-cell chronic lymphocytic leu-
kemia: evidence of caspase activation and apoptosis induction. Blood. 
2002;99(3):1038–1043.
7.  Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J. The 
  chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell 
chronic lymphocytic leukemia cells through a p38 mitogen acti-
vated   protein-kinase-dependent mechanism. Blood. 2002;99(4): 
1314–1319.
8.  Treon SP, Mitsiades C, Mitsiades N, et al. Tumor cell expression of CD59 
is associated with resistance to CD20 serotherapy in patients with B-cell 
malignancies. J Immunother. 2001;24(3):263–271.
9.  Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the 
in vitro susceptibility to rituximab and complement of B-cell chronic 
lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 
20011;98(12):3383–3389.
  10.  Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial 
using escalating single-dose infusion of chimeric anti-CD20 monoclonal 
antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. 
Blood. 1994;84(8):2457–2466.
  11.  Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results 
of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s 
lymphoma. J Clin Oncol. 1997;15(10):3266–3274.
  12.  McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab   chimeric anti-
CD20 monoclonal antibody therapy for relapsed indolent   lymphoma: 
half of patients respond to a four-dose treatment program. J Clin Oncol. 
1998;16(8):2825–2833.
  13.  Nguyen DT, Amess JA, Doughty H, Hendry L, Diamond LW. IDEC-
C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-
grade non-Hodgkin’s lymphoma and lymphoproliferative   disorders: 
evaluation of response on 48 patients. Eur J Haematol. 1999;62(2): 
76–82.
  14.  Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. 
Cytokine-release syndrome in patients with B-cell chronic   lymphocytic 
leukemia and high lymphocyte counts after treatment with an 
  anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 
1999;94(7):2217–2224.
  15.  Ladetto M, Bergui L, Ricca I, Campana S, Pileri A, Tarella C.   Rituximab 
anti-CD20 monoclonal antibody induces marked but transient 
  reductions of peripheral blood lymphocytes in chronic lymphocytic 
leukaemia patients. Med Oncol. 2000;17(3):203–210.
  16.  Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of 
patients with B-cell chronic lymphocytic leukemia. Blood. 2001; 
98(5):1326–1331.
  17.  Itala M, Geisler CH, Kimby E, et al. Standard-dose anti-CD20 
  antibody rituximab has efficacy in chronic lymphocytic leukaemia: 
results from a Nordic multicentre study. Eur J Haematol. 2002;69(3): 
129–134.
  18.  O’Brien SM, Kantarjian H, Thomas DA, et al. Rituximab   dose-escalation 
trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19(8): 
2165–2170.
  19.  Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly 
dosing schedule in B-cell chronic lymphocytic leukemia and small 
lymphocytic lymphoma demonstrates clinical activity and acceptable 
toxicity. J Clin Oncol. 2001;19(8):2153–2164.
  20.  Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as 
first-line and maintenance treatment for patients with chronic lym-
phocytic leukemia or small lymphocytic lymphoma: a phase II trial 
of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003; 
21(9):1746–1751.
  21.  Thomas DA, O’Brien S, Giles FJ, et al. Single agent retuxan in early 
stage chronic lymphocytic leukemia (CLL). ASH Annual Meeting 
Abstracts. 2001;98:Abstract 364a.
  22.  Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of 
fludarabine with concurrent versus sequential treatment with rituximab 
in symptomatic, untreated patients with B-cell chronic lymphocytic 
leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 
9712). Blood. 2003;101(1):6–14.
  23.  Woyach JA, Ruppert AS, Heerema NA, et al. Treatment with flu-
darabine and rituximab produces extended overall survival (OS) and 
progression-free survival (PFS) in chronic lymphocytic leukemia 
(CLL) without increased risk of second malignancy: long-term follow 
up of CALGB Study 9712. Blood (ASH Annual Meeting Abstracts). 
2009;114(22):Abstract 539.
  24.  Schulz H, Klein SK, Rehwald U, et al. Phase 2 study of a com-
bined immunochemotherapy using rituximab and fludarabine in 
patients with chronic lymphocytic leukemia. Blood. 2002;100(9): 
3115–3120.
  25.  Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine 
may prolong progression-free survival and overall survival in patients 
with previously untreated chronic lymphocytic leukemia: an updated 
retrospective comparative analysis of CALGB 9712 and CALGB 9011. 
Blood. 2005;105(1):49–53.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
121
 Rituximab in CLL
  26.  Wierda W, O’Brien S, Wen S, et al. Chemoimmunotherapy with 
fludarabine, cyclophosphamide, and rituximab for relapsed and 
refractory chronic lymphocytic leukemia. J Clin Oncol. 2005; 
23(18):4070–4078.
  27.  Tam CS, O’Brien S, Wierda W, et al. Long-term results of the 
fludarabine, cyclophosphamide, and rituximab regimen as initial 
therapy of chronic lymphocytic leukemia. Blood. 2008;112(4): 
975–980.
  28.  Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoim-
munotherapy regimen of fludarabine, cyclophosphamide, and rituximab 
as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 
2005;23(18):4079–4088.
  29.  Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosph-
amide, and rituximab is an active, well-tolerated regimen for patients 
with previously treated chronic lymphocytic leukemia. J Clin Oncol. 
2006;24(10):1575–1581.
  30.  Kay NE, Geyer SM, Call TG, et al. Combination chemoimmuno-
therapy with pentostatin, cyclophosphamide, and rituximab shows 
significant clinical activity with low accompanying toxicity in pre-
viously untreated B chronic lymphocytic leukemia. Blood. 2007; 
109(2):405–411.
  31.  Hallek M, Fingerle-Rowson G, Fink A-M, et al. Immunochemotherapy 
with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) 
versus fludarabine and cyclophosphamide (FC) improves response rates 
and progression-free survival (PFS) of previously untreated patients 
(pts) with advanced chronic lymphocytic leukemia (CLL). Blood (ASH 
Annual Meeting Abstracts). 2008;112(11):Abstract 325.
  32.  Robak T, Moiseev SI, Dmoszynska A, et al. Rituximab, fludarabine, 
and cyclophosphamide (R-FC) prolongs progression free survival in 
relapsed or refractory chronic lymphocytic leukemia (CLL) compared 
with FC alone: final results from the international randomized phase III 
REACH trial. Blood (ASH Annual Meeting Abstracts). 2008;112(11): 
Abstract lba-1.
  33.  Hallek M, Fingerle-Rowson G, Fink A-M, et al. First-line treatment 
with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) 
improves overall survival (OS) in previously untreated patients (pts) with 
advanced chronic lymphocytic leukemia (CLL): results of a randomized 
phase III trial on behalf of an international group of investigators and 
the German CLL Study Group. Blood (ASH Annual Meeting Abstracts). 
2009;114(22):Abstract 535.
  34.  Wierda WG, O’Brien S, Faderl S, et al. Combined cyclophosphamide, 
fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen 
for heavily treated patients with CLL. Blood (ASH Annual Meeting 
Abstracts). 2006;108(11):Abstract 31.
  35.  Wierda WG, O’Brien S, Ferrajoli A, et al. Combined cyclophosphamide, 
fludarabine, alemtuzumab, and rituximab (CFAR), an active frontline 
regimen for high-risk patients with CLL. Blood (ASH Annual Meeting 
Abstracts). 2007;110(11):Abstract 628.
  36.  Parikh SA, Keating M, O’Brien S, et al. Frontline combined chemoim-
munotherapy with fludarabine, cyclophosphamide, alemtuzumab and 
rituximab (CFAR) in high-risk chronic lymphocytic leukemia. Blood 
(ASH Annual Meeting Abstracts). 2009;114(22):Abstract 208.
37.  Fischer K, Stilgenbauer S, Schweighofer CD, et al. Bendamustine in 
combination with rituximab (BR) for patients with relapsed chronic 
lymphocytic leukemia (CLL): A multicentre phase II trial of the German 
CLL Study Group (GCLLSG). Blood (ASH Annual Meeting Abstracts). 
2008;112(11):Abstract 330.
38.  Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with 
rituximab (BR) in first-line therapy of advanced CLL: a multicenter 
phase II trial of the German CLL Study Group (GCLLSG). Blood (ASH 
Annual Meeting Abstracts). 2009;114(22):Abstract 205.
  39.  Keating MJ, Flinn I, Jain V , et al. Therapeutic role of alemtuzumab 
(Campath-1H) in patients who have failed fludarabine: results of a large 
international study. Blood. 2002;99(10):3554–3561.
  40.  Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with 
chlorambucil as first-line therapy for chronic lymphocytic leukemia. 
J Clin Oncol. 2007;25(35):5616–5623.
  41.  Faderl S, Thomas DA, O’Brien S, et al. Experience with alemtuzumab 
plus rituximab in patients with relapsed and refractory lymphoid malig-
nancies. Blood. 2003;101(9):3413–3415.
  42.  Zent CS, Call TG, Shanafelt TD, et al. Early treatment of high-risk 
chronic lymphocytic leukemia with alemtuzumab and rituximab. Can-
cer. 2008;113(8):2110–2118.
  43.  Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of 
lenalidomide in patients with relapsed or refractory chronic lym-
phocytic leukemia: results of a phase II study. J Clin Oncol. 2006; 
24(34):5343–5349.
  44.  Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete 
and partial remissions in patients with relapsed and refractory chronic 
lymphocytic leukemia. Blood. 2008;111(11):5291–5297.
  45.  Chen C, Paul H, Xu W, et al. A Phase II Study of lenalidomide 
in previously untreated, symptomatic chronic lymphocytic leukemia 
(CLL). Blood (ASH Annual Meeting Abstracts). 2008;112(11): 
Abstract 44.
  46.  Ferrajoli A, Badoux XC, O’Brien S, et al. Combination therapy with 
lenalidomide and rituximab in patients with relapsed chronic lympho-
cytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts). 2009; 
114(22):Abstract 206.
  47.  Thornton PD, Matutes E, Bosanquet AG, et al. High dose methylpred-
nisolone can induce remissions in CLL patients with p53 abnormalities. 
Ann Hematol. 2003;82(12):759–765.
  48.  Bowen DA, Call TG, Jenkins GD, et al. Methylprednisolone-rituximab is 
an effective salvage therapy for patients with relapsed chronic lympho-
cytic leukemia including those with unfavorable cytogenetic features. 
Leuk Lymphoma. 2007;48(12):2412–2417.
 49.  James AF, Castro JE, Sandoval-Sus JD, et al. Rituximab and high-dose 
methylprednisolone for the initial treatment of chronic lymphocytic leukemia 
is associated with promising clinical activity and minimal hematologic toxic-
ity. Blood (ASH Annual Meeting Abstracts). 2008;112(11):Abstract 47.
  50.  Venugopal P, Sivaraman S, Huang XK, Nayini J, Gregory SA, 
Preisler HD. Effects of cytokines on CD20 antigen expression on tumor 
cells from patients with chronic lymphocytic leukemia. Leuk Res. 2000; 
24(5):411–415.
  51.  Ferrajoli A. Incorporating the use of GM-CSF in the treatment of chronic 
lymphocytic leukemia. Leuk Lymphoma. 2009;50(3):514–516.
  52.  Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leu-
koencephalopathy after rituximab therapy in HIV-negative patients: 
a report of 57 cases from the Research on Adverse Drug Events and 
Reports project. Blood. 2009;113(20):4834–4840.
  53.  Niscola P, Del Principe MI, Maurillo L, et al. Fulminant B hepatitis in 
a surface antigen-negative patient with B-cell chronic lymphocytic leu-
kaemia after rituximab therapy. Leukemia. 2005;19(10):1840–1841.
  54.  Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in 
lymphoma patients with prior resolved hepatitis B undergoing anticancer 
therapy with or without rituximab. J Clin Oncol. 2009;27(4):605–611.
  55.  Shanafelt TD, Lin T, Geyer SM, et al. Pentostatin, cyclophosphamide, 
and rituximab regimen in older patients with chronic lymphocytic 
leukemia. Cancer. 2007;109(11):2291–2298.
  56.  Del Poeta G, Del Principe MI, Buccisano F, et al. Consolidation and 
maintenance immunotherapy with rituximab improve clinical out-
come in patients with B-cell chronic lymphocytic leukemia. Cancer. 
2008;112(1):119–128.
  57.  Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with 
low-dose fludarabine and cyclophosphamide and high dose rituximab 
in previously untreated patients with chronic lymphocytic leukemia. 
J Clin Oncol. 2009;27(4):498–503.
  58.  Nabhan C, Patton D, Gordon LI, et al. A pilot trial of rituximab and 
alemtuzumab combination therapy in patients with relapsed and/or 
refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 
2004;45(11):2269–2273.
  59.  Frankfurt O, Hamilton E, Duffey S, et al. Alemtuzumab and rituximab 
Combination Therapy for Patients with Untreated CLL – a Phase II 
Trial. Blood (ASH Annual Meeting Abstracts). 2008;112(11):Abstract 
2098.Journal of Blood Medicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/Journal-of-blood-medicine-journal
The Journal of Blood Medicine is an international, peer-reviewed, open 
access, online journal publishing laboratory, experimental and clinical aspects 
of all topics pertaining to blood based medicine including but not limited to: 
Transfusion Medicine; Blood collection, Donor issues, Transmittable diseases, 
and Blood banking logistics; Immunohematology; Artificial and alternative 
blood based therapeutics; Hematology; Biotechnology/nanotechnology of 
blood related medicine; Legal aspects of blood medicine; Historical perspec-
tives. The manuscript management system is completely online and includes 
a very quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
122
Al-Kali et al
  60.  Dungarwalla M, Evans SO, Riley U, Catovsky D, Dearden CE, Matutes 
E. High dose methylprednisolone and rituximab is an effective therapy 
in advanced refractory chronic lymphocytic leukemia resistant to flu-
darabine therapy. Haematologica. 2008;93(3):475–476.
  61.  Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. Rituximab 
in combination with high-dose methylprednisolone for the treatment 
of fludarabine refractory high-risk chronic lymphocytic leukemia. 
Leukemia. 2008;22(11):2048–2053.